A prospective, phase I-II, multicenter, open-label study investigating the combination of trabectedin and radiation therapy in patients with soft tissue sarcoma.
Principal Investigator
Dott. Giovanni Grignani
Contact Information for Access
Phase
FASE II
Status
ATTIVO
Objective of the study
The maximum tolerated dose (MTD) will be determined for each cohort, as the patient profile varies along with the radiation dose.
Soft tissue sarcoma.
Sponsor: Grupo Español de Investigación en Sarcomas (GEIS)
Pathologies
Sarcomi tumori rari e GIST
Medication
Trabectedin + Radiation Therapy
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients with soft tissue sarcoma who have received at least one prior treatment.
Back to search page